These findings indicate a potential link between KRT17 expression and sensitivity of organoids to Akt/PI3 kinase inhibition, and suggest that KRT17 merits further investigation as a candidate biomarker and stratification tool in future therapeutic studies targeting Akt/PI3-kinase in the treatment of platinum-resistant, recurrent ovarian cancer. This evidence concerns the gene KRT17 and ovarian carcinoma.